The Distributional Heterogeneity of The Molecular Pathology Characteristics in Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 CHENJie ¹ ,  LüQing ¹ , WANGZhu ² , DUZheng-gui ¹ , TANQiu-wen ¹ , WANGQiang ² , ZENGHe-lin ¹

1.Department of Thyroid and Breast Surgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China;
2.Laboratory of Tumor Molecular Diagnosis, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China;

Corresponding author：

LüQing, Email: lqlq1963@163.com

Keywords：

Heterogeneity; Breast cancer; Estrogen receptor; Progesterone receptor; Human epidermal growth factor receptor-2; Ki-67

DOI：

10.7507/1007-9424.20160200

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the research progress of distributional heterogeneity of the molecular pathology characteristics in breast cancer. Methods The related literatures about the distribution of the molecular pathology characteristics in breast cancer were reviewed. Results The breast cancer had the same heterogeneity as other cancers. At the same time, the molecular pathology characteristics, such as estrogen receptor (ER), progesterone receptor (PR), Ki-67, and human epidermal growth factor receptor-2 (HER-2), had the distributional heterogeneity. The distributional heterogeneity of molecular pathology characteristics in breast cancer could effect the pathologic diagnosis, the treatment, and the prognosis. Conclusion Although there are some new techniques which were used to investigate the heterogeneity of breast cancer, but each way has some problems. The more attention should be paid to the research about the distributional heterogeneity of the molecular pathology characteristics in breast cancer.

Citation： CHENJie, LüQing, WANGZhu, DUZheng-gui, TANQiu-wen, WANGQiang, ZENGHe-lin. The Distributional Heterogeneity of The Molecular Pathology Characteristics in Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(6): 761-765. doi: 10.7507/1007-9424.20160200 Copy

1.	Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
2.	American Cancer Society. Cancer facts and statistics 2015. 2015-08-15. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf..
3.	NCCN. NCCN clinical practice guidelines in oncology: breast cancer. 2014-09-04. http://www. NCCN.com..
4.	Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.
5.	Fitzgibbons PL, Dillon DA, Alsabeh R, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med, 2014, 138(5): 595-601.
6.	Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justifica-tion of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor hetero-geneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol, 2007, 25(34): 5418-5425.
7.	Pritchard KI. The best use of adjuvant endocrine treatments. Breast, 2003, 12(6): 497-508.
8.	Zardavas D, Irrthum A, Swanton C, et al. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol, 2015, 12(7): 381-394.
9.	Beca F, Polyak K. Intratumor heterogeneity in breast cancer. Adv Exp Med Biol, 2016, 882: 169-189.
10.	Bryne M. Prognostic value of various molecular and cellular features in oral squamous cell carcinomas: a review. J Oral Pathol Med, 1991, 20(9): 413-420.
11.	Yarbro JW. Breast cancer: the new biology in conflict with the old dogma. Semin Oncol Nurs, 1985, 1(3): 157-162.
12.	张伟, 林宜先, 熊永炎. 肺癌异质性的分子病理学研究. 肿瘤防治研究, 2001, 28(6): 487-489.
13.	李岩磊, 栾雅静, 仇晓菲, 等. CD44在小细胞肺癌中的异质性表达及意义. 天津医科大学学报, 2011, 17(4): 451-454.
14.	刘丽江, 舒细记, 镇鸿燕, 等. 胃腺癌组织学异质性与淋巴结转移程度相关. 世界华人消化杂志, 2004, 12(6): 1273-1276.
15.	Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 2012, 366(10): 883-892.
16.	于丹, 金春顺, 赵黎明, 等. 人喉癌细胞异质性亚群的克隆分离及性质初探. 中国耳鼻咽喉头颈外科, 2009, 16(1): 17-20.
17.	Arnerlöv C, Emdin SO, Cajander S, et al. Intratumoral variations in DNA ploidy and s-phase fraction in human breast cancer. Anal Cell Pathol, 2001, 23(1): 21-28.
18.	田海梅, 傅军, 曹冬艳, 等. 人乳腺癌细胞异质性及其生物学行为研究. 中华肿瘤杂志, 2003, 25(6): 535-537.
19.	许健, 张颂, 王水. MCF-7异质性及肿瘤干细胞相关亚群初步研究. 中华肿瘤防治杂志, 2013, 20(14): 1070-1074.
20.	Burchiel SW, Martin JC, Imai K, et al. Heterogeneity of HLA-A,B,Ⅰa-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry. Cancer Res, 1982, 42(10): 4110-4115.
21.	龚西騟, 孟刚. 乳腺癌肿瘤相关抗原表达异质性的研究. 安徽医科大学学报, 1992, 27(4): 256-258.
22.	Tilley WD, Keightley DD, Cant EL. Inter-site variation of oestrogen receptors in human breast cancers. Br J Cancer, 1978, 38(4): 544-546.
23.	Taylor CR, Cooper CL, Kurman RJ, et al. Detection of estrogen receptor in breast and endometrial carcinoma by the immunopero-xidase technique. Cancer, 1981, 47(11): 2634-2640.
24.	Chung GG, Zerkowski MP, Ghosh S, et al. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest, 2007, 87(7): 662-669.
25.	Ito T, Sato N, Yamaguchi Y, et al. Differences in stemness properties associated with the heterogeneity of luminal-type breast cancer. Clin Breast Cancer, 2015, 15(2): e93-e103.
26.	Pape-Zambito D, Jiang Z, Wu H, et al. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients. PLos One, 2014, 9(6): e100488.
27.	Himuro T, Horimoto Y, Arakawa A, et al. Ki67 heterogeneity in estrogen receptor-positive breast cancers: which tumor type has the most heterogeneity?. Int J Surg Pathol, 2016, 24(2): 103-107.
28.	Douglas-Jones AG, Collett N, Morgan JM, et al. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol, 2001, 54(12): 951-955.
29.	Chen C, Xia HS, Gong YP, et al. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis. Biomaterials, 2010, 31(33): 8818-8825.
30.	Lehmann U, Glöckner S, Kleeberger W, et al. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol, 2000, 156(6): 1855-1864.
31.	Ohlschlegel C, Zahel K, Kradolfer D, et al. HER2 genetic heteroge-neity in breast carcinoma. J Clin Pathol, 2011, 64(12): 1112-1116.
32.	Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological signifi-cance. Mod Pathol, 2012, 25(7): 938-948.
33.	Denkert C, Budczies J, von Minckwitz G, et al. Strategies for develo-ping Ki67 as a useful biomarker in breast cancer. Breast, 2015, 24(Suppl 2): S67-S72.
34.	陈志萍, 李金高, 黄传生. ER、PR及HER-2受体在乳腺癌原发灶及复发灶间表达差异及意义. 临床医药实践, 2009, 2(14): 1653-1655.
35.	汤钊猷. 现代肿瘤学. 第2版. 上海: 上海医科大学出版社, 2000: 95-96.
36.	Riviére A, Wilckens C, Löning T. Expression of c-erbB2 and c-myc in squamous epithelia and squamous cell carcinomas of the head and neck and the lower female genital tract. J Oral Pathol Med, 1990, 19(9): 408-413.
37.	Brunelli M, Manfrin E, Martignoni G, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol, 2009, 131(5): 678-682.
38.	Park SY, Goenen M, Kim HJ, et al. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest, 2010, 120(2): 636-644.
39.	颜政, 方驰华. 人肝细胞癌细胞亚群的克隆分离及异质性机制的初步研究. 世界华人消化杂志, 2006, 14(5): 481-485.
40.	Melchor L, Molyneux G, Mackay A, et al. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol, 2014, 233(2): 124-137.
41.	Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle, 2007, 6(19): 2332-2338.
42.	Dai X, Li Y, Bai Z, et al. Molecular portraits revealing the hetero-geneity of breast tumor subtypes defined using immunohistoche-mistry markers. Sci Rep, 2015, 5: 14499.
43.	van Keymeulen A, Lee MY, Ousset M, et al. Reactivation of multipo-tency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature, 2015, 525(7567): 119-123.
44.	Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell, 2012, 10(6): 717-728.
45.	Raghu M, Hooley R. Breast ultrasound for the interventionalist. Tech Vasc Interv Radiol, 2014, 17(1): 16-22.
46.	Youk JH, Kim EK, Kim MJ, et al. Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2 420 cases with long-term follow-up. Am J Roentgenol, 2008, 190(1): 202-207.
47.	Jankowski C, Hudry D, Vaillant D, et al. Evaluation of axillary involvement by ultrasound-guided lymph node biopsy: a prospective study. Gynecol Obstet Fertil, 2015, 43(6): 431-436.
48.	Myers KS, Kamel IR, Macura KJ. MRI-guided breast biopsy: outcomes and effect on patient management. Clin Breast Cancer, 2015, 15(2): 143-152.
49.	Crowe JP Jr, Patrick RJ, Rybicki LA, et al. Does ultrasound core breast biopsy predict histologic finding on excisional biopsy?. Am J Surg, 2003, 186(4): 397-399.
50.	Gonçalves AV, Thuler LC, Kestelman FP, et al. Underestimation of malignancy of core needle biopsy for nonpalpable breast lesions. Rev Bras Ginecol Obstet, 2011, 33(7): 123-131.
51.	Dekker TJ, Smit VT, Hooijer GK, et al. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Ann Oncol, 2013, 24(4): 931-937.
52.	Sutela A, Vanninen R, Sudah M, et al. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. Acta Oncol, 2008, 47(1): 38-46.
53.	Chen X, Yuan Y, Gu Z, et al. Accuracy of estrogen receptor, proges-terone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat, 2012, 134(3): 957-967.
54.	Seferina SC, Nap M, van den Berkmortel F, et al. Reliability of receptor assessment on core needle biopsy in breast cancer patients. Tumour Biol, 2013, 34(2): 987-994.
55.	Ricci MD, Calvano Filho CM, Oliveira Filho HR, et al. Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. Rev Assoc Med Bras, 2012, 58(5): 532-536.
56.	Greer LT, Rosman M, Mylander W, et al. Does breast tumor hetero-geneity necessitate further immunohistochemical staining on surgical specimens?. J Am Coll Surg, 2013，216(2): 239-251.
57.	Ough M, Velasco J, Hieken TJ. A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression. Am J Surg, 2011, 201(5): 692-694.
58.	Dai X, Chen A, Bai Z. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. Sci Rep, 2014, 4: 6566.
59.	Yang Z, Sun Y, Zhang Y, et al. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?. Clin Breast Cancer, 2013, 13(5): 359-363.
60.	Han X, Shi Y, Ma L, et al. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3 149 Chinese patients. Chin Med J (Engl), 2014, 127(2): 246-253.
61.	Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol, 1998, 11(2): 155-168.
62.	Lower EE, Glass E, Blau R, et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat, 2009, 113(2): 301-306.
63.	Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist, 2008, 13(8): 838-844.
64.	Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer, 2014, 50(2): 277-289.
65.	徐兵河, 胡夕春, 江泽飞, 等. 中国晚期乳腺癌诊治专家共识 . 北京: 人民卫生出版社, 2015: 17-18.
66.	Ji H, Xuan Q, Nanding A, et al. The clinicopathologic and prognostic value of altered chromosome 17 centromere copy number in HER2 fish equivocal breast carcinomas. PLoS One, 2015, 10(7): e0132824.
67.	Hammond ME, Hayes DF, Wolff AC, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract, 2010, 6(4): 195-197.
68.	Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol, 2013, 31(31): 3997-4013.
69.	《乳腺癌HER2检测指南(2009版)》编写组. 乳腺癌HER2检测指南(2009版). 中华病理学杂志, 2009, 38(12): 836-840.
70.	van Baardwijk A, Bosmans G, van Suylen RJ, et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol, 2008, 87(1): 55-58.
71.	Kurland BF, Peterson LM, Lee JH, et al. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med, 2011, 52(10): 1541-1549.
72.	Currin E, Peterson LM, Schubert EK, et al. Temporal heterogeneity of estrogen receptor expression in bone-dominant breast cancer: 18F-fluoroestradiol PET imaging shows return of ER expression. J Natl Compr Canc Netw, 2016, 14(2): 144-147.
73.	Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med, 2002, 8(11): 1323-1327.

1. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
2. American Cancer Society. Cancer facts and statistics 2015. 2015-08-15. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf..
3. NCCN. NCCN clinical practice guidelines in oncology: breast cancer. 2014-09-04. http://www. NCCN.com..
4. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.
5. Fitzgibbons PL, Dillon DA, Alsabeh R, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med, 2014, 138(5): 595-601.
6. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justifica-tion of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor hetero-geneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol, 2007, 25(34): 5418-5425.
7. Pritchard KI. The best use of adjuvant endocrine treatments. Breast, 2003, 12(6): 497-508.
8. Zardavas D, Irrthum A, Swanton C, et al. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol, 2015, 12(7): 381-394.
9. Beca F, Polyak K. Intratumor heterogeneity in breast cancer. Adv Exp Med Biol, 2016, 882: 169-189.
10. Bryne M. Prognostic value of various molecular and cellular features in oral squamous cell carcinomas: a review. J Oral Pathol Med, 1991, 20(9): 413-420.
11. Yarbro JW. Breast cancer: the new biology in conflict with the old dogma. Semin Oncol Nurs, 1985, 1(3): 157-162.
12. 张伟, 林宜先, 熊永炎. 肺癌异质性的分子病理学研究. 肿瘤防治研究, 2001, 28(6): 487-489.
13. 李岩磊, 栾雅静, 仇晓菲, 等. CD44在小细胞肺癌中的异质性表达及意义. 天津医科大学学报, 2011, 17(4): 451-454.
14. 刘丽江, 舒细记, 镇鸿燕, 等. 胃腺癌组织学异质性与淋巴结转移程度相关. 世界华人消化杂志, 2004, 12(6): 1273-1276.
15. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 2012, 366(10): 883-892.
16. 于丹, 金春顺, 赵黎明, 等. 人喉癌细胞异质性亚群的克隆分离及性质初探. 中国耳鼻咽喉头颈外科, 2009, 16(1): 17-20.
17. Arnerlöv C, Emdin SO, Cajander S, et al. Intratumoral variations in DNA ploidy and s-phase fraction in human breast cancer. Anal Cell Pathol, 2001, 23(1): 21-28.
18. 田海梅, 傅军, 曹冬艳, 等. 人乳腺癌细胞异质性及其生物学行为研究. 中华肿瘤杂志, 2003, 25(6): 535-537.
19. 许健, 张颂, 王水. MCF-7异质性及肿瘤干细胞相关亚群初步研究. 中华肿瘤防治杂志, 2013, 20(14): 1070-1074.
20. Burchiel SW, Martin JC, Imai K, et al. Heterogeneity of HLA-A,B,Ⅰa-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry. Cancer Res, 1982, 42(10): 4110-4115.
21. 龚西騟, 孟刚. 乳腺癌肿瘤相关抗原表达异质性的研究. 安徽医科大学学报, 1992, 27(4): 256-258.
22. Tilley WD, Keightley DD, Cant EL. Inter-site variation of oestrogen receptors in human breast cancers. Br J Cancer, 1978, 38(4): 544-546.
23. Taylor CR, Cooper CL, Kurman RJ, et al. Detection of estrogen receptor in breast and endometrial carcinoma by the immunopero-xidase technique. Cancer, 1981, 47(11): 2634-2640.
24. Chung GG, Zerkowski MP, Ghosh S, et al. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest, 2007, 87(7): 662-669.
25. Ito T, Sato N, Yamaguchi Y, et al. Differences in stemness properties associated with the heterogeneity of luminal-type breast cancer. Clin Breast Cancer, 2015, 15(2): e93-e103.
26. Pape-Zambito D, Jiang Z, Wu H, et al. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients. PLos One, 2014, 9(6): e100488.
27. Himuro T, Horimoto Y, Arakawa A, et al. Ki67 heterogeneity in estrogen receptor-positive breast cancers: which tumor type has the most heterogeneity?. Int J Surg Pathol, 2016, 24(2): 103-107.
28. Douglas-Jones AG, Collett N, Morgan JM, et al. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol, 2001, 54(12): 951-955.
29. Chen C, Xia HS, Gong YP, et al. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis. Biomaterials, 2010, 31(33): 8818-8825.
30. Lehmann U, Glöckner S, Kleeberger W, et al. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol, 2000, 156(6): 1855-1864.
31. Ohlschlegel C, Zahel K, Kradolfer D, et al. HER2 genetic heteroge-neity in breast carcinoma. J Clin Pathol, 2011, 64(12): 1112-1116.
32. Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological signifi-cance. Mod Pathol, 2012, 25(7): 938-948.
33. Denkert C, Budczies J, von Minckwitz G, et al. Strategies for develo-ping Ki67 as a useful biomarker in breast cancer. Breast, 2015, 24(Suppl 2): S67-S72.
34. 陈志萍, 李金高, 黄传生. ER、PR及HER-2受体在乳腺癌原发灶及复发灶间表达差异及意义. 临床医药实践, 2009, 2(14): 1653-1655.
35. 汤钊猷. 现代肿瘤学. 第2版. 上海: 上海医科大学出版社, 2000: 95-96.
36. Riviére A, Wilckens C, Löning T. Expression of c-erbB2 and c-myc in squamous epithelia and squamous cell carcinomas of the head and neck and the lower female genital tract. J Oral Pathol Med, 1990, 19(9): 408-413.
37. Brunelli M, Manfrin E, Martignoni G, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol, 2009, 131(5): 678-682.
38. Park SY, Goenen M, Kim HJ, et al. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest, 2010, 120(2): 636-644.
39. 颜政, 方驰华. 人肝细胞癌细胞亚群的克隆分离及异质性机制的初步研究. 世界华人消化杂志, 2006, 14(5): 481-485.
40. Melchor L, Molyneux G, Mackay A, et al. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol, 2014, 233(2): 124-137.
41. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle, 2007, 6(19): 2332-2338.
42. Dai X, Li Y, Bai Z, et al. Molecular portraits revealing the hetero-geneity of breast tumor subtypes defined using immunohistoche-mistry markers. Sci Rep, 2015, 5: 14499.
43. van Keymeulen A, Lee MY, Ousset M, et al. Reactivation of multipo-tency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature, 2015, 525(7567): 119-123.
44. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell, 2012, 10(6): 717-728.
45. Raghu M, Hooley R. Breast ultrasound for the interventionalist. Tech Vasc Interv Radiol, 2014, 17(1): 16-22.
46. Youk JH, Kim EK, Kim MJ, et al. Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2 420 cases with long-term follow-up. Am J Roentgenol, 2008, 190(1): 202-207.
47. Jankowski C, Hudry D, Vaillant D, et al. Evaluation of axillary involvement by ultrasound-guided lymph node biopsy: a prospective study. Gynecol Obstet Fertil, 2015, 43(6): 431-436.
48. Myers KS, Kamel IR, Macura KJ. MRI-guided breast biopsy: outcomes and effect on patient management. Clin Breast Cancer, 2015, 15(2): 143-152.
49. Crowe JP Jr, Patrick RJ, Rybicki LA, et al. Does ultrasound core breast biopsy predict histologic finding on excisional biopsy?. Am J Surg, 2003, 186(4): 397-399.
50. Gonçalves AV, Thuler LC, Kestelman FP, et al. Underestimation of malignancy of core needle biopsy for nonpalpable breast lesions. Rev Bras Ginecol Obstet, 2011, 33(7): 123-131.
51. Dekker TJ, Smit VT, Hooijer GK, et al. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Ann Oncol, 2013, 24(4): 931-937.
52. Sutela A, Vanninen R, Sudah M, et al. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. Acta Oncol, 2008, 47(1): 38-46.
53. Chen X, Yuan Y, Gu Z, et al. Accuracy of estrogen receptor, proges-terone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat, 2012, 134(3): 957-967.
54. Seferina SC, Nap M, van den Berkmortel F, et al. Reliability of receptor assessment on core needle biopsy in breast cancer patients. Tumour Biol, 2013, 34(2): 987-994.
55. Ricci MD, Calvano Filho CM, Oliveira Filho HR, et al. Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. Rev Assoc Med Bras, 2012, 58(5): 532-536.
56. Greer LT, Rosman M, Mylander W, et al. Does breast tumor hetero-geneity necessitate further immunohistochemical staining on surgical specimens?. J Am Coll Surg, 2013，216(2): 239-251.
57. Ough M, Velasco J, Hieken TJ. A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression. Am J Surg, 2011, 201(5): 692-694.
58. Dai X, Chen A, Bai Z. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. Sci Rep, 2014, 4: 6566.
59. Yang Z, Sun Y, Zhang Y, et al. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?. Clin Breast Cancer, 2013, 13(5): 359-363.
60. Han X, Shi Y, Ma L, et al. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3 149 Chinese patients. Chin Med J (Engl), 2014, 127(2): 246-253.
61. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol, 1998, 11(2): 155-168.
62. Lower EE, Glass E, Blau R, et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat, 2009, 113(2): 301-306.
63. Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist, 2008, 13(8): 838-844.
64. Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer, 2014, 50(2): 277-289.
65. 徐兵河, 胡夕春, 江泽飞, 等. 中国晚期乳腺癌诊治专家共识 . 北京: 人民卫生出版社, 2015: 17-18.
66. Ji H, Xuan Q, Nanding A, et al. The clinicopathologic and prognostic value of altered chromosome 17 centromere copy number in HER2 fish equivocal breast carcinomas. PLoS One, 2015, 10(7): e0132824.
67. Hammond ME, Hayes DF, Wolff AC, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract, 2010, 6(4): 195-197.
68. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol, 2013, 31(31): 3997-4013.
69. 《乳腺癌HER2检测指南(2009版)》编写组. 乳腺癌HER2检测指南(2009版). 中华病理学杂志, 2009, 38(12): 836-840.
70. van Baardwijk A, Bosmans G, van Suylen RJ, et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol, 2008, 87(1): 55-58.
71. Kurland BF, Peterson LM, Lee JH, et al. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med, 2011, 52(10): 1541-1549.
72. Currin E, Peterson LM, Schubert EK, et al. Temporal heterogeneity of estrogen receptor expression in bone-dominant breast cancer: 18F-fluoroestradiol PET imaging shows return of ER expression. J Natl Compr Canc Netw, 2016, 14(2): 144-147.
73. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med, 2002, 8(11): 1323-1327.

Previous Article
Understanding and Application of Enteral Nutrition Support
Next Article
Application Progress of MRI in Assessment of Rectal Cancer Before Surgery

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The Distributional Heterogeneity of The Molecular Pathology Characteristics in Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content